GlassScriptPhysician profile
Nicole Oliver
NPI 1952533663
$2,134.97
in general payments reported to CMS, 2019-2025
30 companies · $600 in 2025
The $600 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $173 · 2021: $288 · 2022: $204 · 2023: $370 · 2024: $186 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $518.48 | 2019-2023 | |
| Astellas Pharma US INC | $244.21 | 2023-2025 | Veozah, Myrbetriq |
| Organon LLC | $227.27 | 2021-2025 | Nexplanon, Jada System |
| Coopersurgical, INC. | $123.13 | 2020-2025 | Paragard T 380a, Paragard T 380a, Sos |
| Bayer Healthcare Pharmaceuticals INC. | $111.85 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $95.30 | 2021-2025 | |
| Pfizer INC. | $73.99 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $69.99 | 2025 | Myfembree |
| Aspira Women'S Health INC | $64.34 | 2023-2024 | Ova1 |
| Bard Access Systems, INC. | $56.54 | 2019 | |
| Biogen, INC. | $50.05 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $48.16 | 2025 | |
| Hologic Sales and Service, LLC | $45.91 | 2023-2024 | Aptima |
| Vertex Pharmaceuticals Incorporated | $43.29 | 2024-2025 | |
| Exact Sciences Corporation | $39.82 | 2023 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $33.20 | 2019 | |
| Therapeuticsmd, INC. | $33.14 | 2020-2021 | |
| Medtronic, INC. | $28.09 | 2023-2025 | Ligasure, Truclear |
| Agile Therapeutics, INC. | $26.73 | 2022 | |
| Olympus America INC. | $24.86 | 2025 | Olympus |
| Amgen INC. | $24.14 | 2019 | |
| Myovant Sciences INC. | $22.76 | 2021 | |
| Bard Peripheral Vascular, INC. | $21.56 | 2021 | |
| Ethicon US, LLC | $16.76 | 2019 | |
| Millicent US INC | $16.34 | 2025 | Intrarosa, Femlyv |
| Avion Pharmaceuticals | $16.33 | 2021 | |
| Merck Sharp & Dohme LLC | $15.82 | 2023 | Gardasil 9 |
| Mylan Pharmaceuticals INC. | $15.14 | 2022 | |
| Minerva Surgical, INC | $14.61 | 2019 | |
| Medicem INC. | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.